1.Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial.
Yan-Yan WANG ; Xiao-Mei SHENG ; Rong-Yan ZHANG ; Xiao-Nan GUO ; Hui SUN ; Xin WANG ; Jin-Lin ZHANG ; Jun-Min LI ; Zhi-Xiang SHEN
Chinese Journal of Hematology 2010;31(11):748-751
OBJECTIVETo compare the effectiveness and side effects of two chemotherapy regimens [pirarubicin + cytarabine (TA) and daunorubicin + cytarabine (DA)] in patients with acute myeloid leukemia (AML).
METHODSFrom Oct 2006 to Jul 2009, there were 207 newly diagnosed AML patients randomized into DA or TA group from 72 centers all over the country. The aim of this clinical trial is to observe and evaluate complete remission rate (CR), total remission rate (TRR), and side effect after one or two circles of therapy.
RESULTSIn 198 evaluable patients, 126 cases in TA group and 72 in DA group were evalvable, with a ratio of 1.75:1. CR was 69.8% and TRR (CR + PR) was 81.8% in TA group and 63.9%, 80.9% in DA group, correspondingly (P > 0.05). For patients with subtype M(2), CR (77.1%) in TA group was higher than that in DA (60%). There was no difference in side effect between the two groups.
CONCLUSIONThere is no difference of the effect between TA and DA chemotherapy for newly diagnosed AML patients. But for subtype M(2), TA is more efficacy. And there is no difference in side effect between the two regimens.
Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Cytarabine ; administration & dosage ; Daunorubicin ; administration & dosage ; Humans ; Leukemia, Myeloid, Acute ; drug therapy ; Prospective Studies
3.Clinical study of COAD-B regimen in treatment of patients with relapsed/refractory non-Hodgkin lymphoma.
Ming-hui LI ; Yu-fu LI ; Qing-song YIN ; Rui-hua MI ; Lin CHEN ; Jian-wei DU ; Xu-dong WEI
Chinese Journal of Hematology 2013;34(10):857-861
OBJECTIVETo investigate the efficacy, adverse events and long-term survival of cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin (COAD-B) regimen for relapsed and refractory non-Hodgkin lymphoma (NHL).
METHODSEighty six patients diagnosed with relapsed or refractory NHL were included in our study from January 2007 to January 2013. The chemotherapy regimen was COAD-B, the therapeutic efficacy was evaluated every 2 courses. Once the stable disease (SD) or progress of the disease (PD) achieved, the patients would switch to other second-line regimens.
RESULTSThe overall response rate (ORR) was 67.4%, median remission duration was 13 months (3-51 months); 1-,2- and 4-year overall survival (OS) rates were 75.4%, 56.8% and 40.0%, respectively; 1-, 2- and 4-year progression-free survival (PFS) rates were 50.3%, 39.4% and 27.5%, respectively. The main adverse reaction of patients was myelosuppression. The response to chemotherapy and long- term survival of the relapsed patients were significantly better than that of the refractory ones, and the difference had statistical significance.
CONCLUSIONCOAD-B could be the salvage regimen for relapsed and refractory NHL.
Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Bleomycin ; administration & dosage ; Cyclophosphamide ; administration & dosage ; Cytarabine ; administration & dosage ; Dexamethasone ; administration & dosage ; Disease-Free Survival ; Humans ; Lymphoma, Non-Hodgkin ; drug therapy ; Remission Induction ; Salvage Therapy ; Survival Rate ; Treatment Outcome ; Vindesine ; administration & dosage
4.The use of cytosine arabinoside in glaucoma filtering surgery.
Korean Journal of Ophthalmology 1992;6(2):62-68
Posterior lip sclerectomies were performed in rabbits and cytosine arabinoside (Ara-C) was applied by topical instillation or subconjunctival injection. In both groups, the mean intraocular pressure (IOP) of the treated eyes was significantly lowered at postoperative week 1 and 2, but there was no significant difference between the mean IOP of the control eyes and that of the treated eyes at postoperative week 3 and 4. In both groups, at postoperative week 2, the sclerectomy sites of the control eyes were totally occluded by granulation tissue, but those of the treated eyes were partially replaced by granulation tissue. At postoperative week 4, the sclerectomy sites of the treated eyes were totally occluded by the granulation tissue ultimately in both groups. There were no differences in the mean IOP and the histologic finding of the treated eyes between the topical instillation group and the subconjunctival injection group. We concluded that either topical instillation or subconjunctival injection of Ara-C can delay wound healing at the surgical site after glaucoma filtering surgery in rabbits.
Administration, Topical
;
Animals
;
Conjunctiva
;
Cytarabine/*administration & dosage/therapeutic use
;
Glaucoma/pathology/*surgery
;
Injections
;
Intraocular Pressure/drug effects
;
Ophthalmic Solutions
;
Rabbits
;
*Sclerostomy
;
Wound Healing/drug effects
5.A Case of Successful Intrapleural Chemotherapy with Cisplatin Plus Cytarabine for Intractable Malignant Pleural Effusion.
Yong Wha MOON ; Sang Tae CHOI ; Byoung Chul CHO ; Hye Jin CHOI ; Yong Tai KIM
Yonsei Medical Journal 2007;48(6):1035-1038
When conventional treatments of malignant pleural effusion, such as repeated thoracentesis, closed thoracotomy and pleurodesis by instilled sclerosing agents, are ineffective, there are few alternative therapies available. Our case involves a 47-year-old woman with uterine cervical carcinoma suffering from malignant pleural effusion. She presented with a chief complaint of severe dyspnea, and was classified as an Eastern Cooperative Oncology Group (ECOG) performance status of 4. Her underlying cervical carcinoma progressed despite various systemic chemotherapy regimens. In addition, pleural effusion persisted in spite of 4 weeks of drainage through the thoracotomy tube and talc pleurodesis. Under such circumstances, we attempted intrapleural chemotherapy with cisplatin plus cytarabine, which resulted in significant decrease of the pleural effusion. No serious systemic toxicities, including myelosuppression, were observed. As a result, the patient's dyspnea was relieved, and her ECOG performance status improved from 4 to 2. However, the thoracotomy tube was not removed due to subsequent iatrogenic pneumothorax. Pleural effusion did not recur for the 4 weeks leading up to her death.
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Cisplatin/administration & dosage
;
Cytarabine/administration & dosage
;
Fatal Outcome
;
Female
;
Humans
;
Middle Aged
;
Pleural Effusion, Malignant/*drug therapy
;
Treatment Outcome
6.Clinical curative efficacy of inducing remission for the newly diagnosed aged AML patients by chemotherapy with IA and DA regimens.
Dong-Hua TIAN ; Si-Lin GAN ; Hai-Zhou XING ; Yan-Fang LIU ; Xin-Sheng XIE ; Hui SUN
Journal of Experimental Hematology 2014;22(5):1282-1285
This study was aimed to explore the clinical efficacy and toxicity of idarubicin (IA regimen) and daunoru-bicin combined with cytarabine (DA regimen) for treating aged patients with AML as induction chemotherapy. The clinical data of 60 newly diagnosed AML aged patients treated with IA or DA regimen were analyzed retrospectively. IA regimen group included 22 patients (8 male and 14 females with median age of 66 yrs), while the DA regimen group included 38 patients (20 males and 18 females with median age of 64 yrs). The complete remission rate, total effective rate and adverse effects after one chemotherapy course were compared. The results showed that the CR rate in IA regimen group was 63.63%, which was significantly higer than that in DA regimen group (31.58%) (P < 0.05). The total effective rate was 63.63% and 36.84% respectively in IA and DA regimen groups, there was significant difference between the two groups (P < 0.05). Both the hematological and non-hematological adverse effects were observed and no difference was found in the two regimen groups, neither in myelosupression (P > 0.05), the major hematological adverse effects, nor in non-hematological adverse effects (P > 0.05). It is concluded that for aged AML patients, IA regimen can achieve a higher CR rate and higher total effective rate than that in DA regimen without increase of adverse effects after one induction chemotherapy course.
Aged
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Cytarabine
;
administration & dosage
;
Female
;
Humans
;
Idarubicin
;
administration & dosage
;
Induction Chemotherapy
;
Leukemia, Myeloid, Acute
;
drug therapy
;
Male
;
Middle Aged
;
Retrospective Studies
7.Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia.
Yi-Yun YAO ; Qi ZHU ; Li-Fang ZOU ; Hong-Ju DOU ; Yi-Min CHEN ; Yong TANG ; Jun-Pei HU
Journal of Experimental Hematology 2009;17(3):774-776
The aim of study was to evaluate the clinical efficacy and toxicity of fludarabine combined with cytarabine (FA) regimen in the treatment of patients with refractory and/or relapsed acute myeloid leukemia (AML). Nineteen cases with refractory/relapsed AML were treated with FA regimen in which fludarabine phosphate 25 mg/(m(2) x d), d1-5; cytarabine (Ara-C) 2 g/(m(2) x d), d1-5. Another 20 cases were treated with salvage chemotherapy (MAE regimen: mitoxantrone, Ara-C and etoposide or DAE regimen: daunorubicin, Ara-C and etoposide). All patients received at least 2 cycles chemotherapy. The results showed that 9 patients (47%) in FA regimen group achieved complete remission (CR), 8 cases (42%) obtained partial remission (PR), the clinical efficacy was superior to that of the MAE or DAE regimens (p < 0.05). Major toxicity of FA regimen was myelosuppression. Grade IV hematologic toxicity occurred in all patients received FA regimen. Nonhematologic complications consisted of gastrointestinal side effects, mucositis, liver toxicity, which were mild to moderate and could be alleviated with supportive therapy. In conclusion, FA regimen is an effective regimen for treatment of refractory and relapsed AML.
Adult
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Cytarabine
;
administration & dosage
;
Female
;
Humans
;
Leukemia, Myeloid, Acute
;
drug therapy
;
Male
;
Middle Aged
;
Recurrence
;
Vidarabine
;
administration & dosage
;
analogs & derivatives
8.Studies on concentrations and interactions of drugs in patients with administration of high-dose of cytosine arabinoside and methotrexate.
Yan-ning QU ; Bin JIANG ; Yu-hang WANG
Chinese Journal of Hematology 2012;33(12):1049-1051
Adolescent
;
Adult
;
Cytarabine
;
administration & dosage
;
blood
;
pharmacology
;
Drug Interactions
;
Female
;
Humans
;
Instillation, Drug
;
Leukemia
;
blood
;
drug therapy
;
Male
;
Methotrexate
;
administration & dosage
;
blood
;
pharmacology
;
Middle Aged
;
Young Adult
9.Observation of low-dose HA/HAA regimen as induction chemotherapy on elderly patients with acute myeloid leukemia.
Dijiong WU ; Baodong YE ; Jianping SHEN ; Yiping SHEN ; Shengyun LIN ; Zhiping HU ; Qinghong YU ; Zhiyin ZHENG ; Laijun PENG ; Shan LIU ; Conghua JI ; Yunfei LUO ; Xiaowen WEN ; Keding SHAO ; Yu ZHANG ; Yanting GAO ; Dan CHEN ; Yuhong ZHOU
Chinese Journal of Hematology 2014;35(3):256-259